ArticleFrontiers in oncology2025
PRESCO: an online tool for predicting severe pulmonary complications and survival after cancer surgery.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe pulmonary complications (SPCs) after cancer surgery have a significant impact on morbidity, mortality, and healthcare burden. Despite this, clinicians currently lack accurate and practical tools to predict the occurrence and survival outcomes of SPCs. Methods: We conducted a retrospective cohort study of cancer patients undergoing surgery at Hunan Cancer Hospital between June 2023 and June 2025. Two datasets were established (1): 434 patients (227 with SPCs and 207 controls) for predicting SPCs occurrence, and (2) 227 SPC patients with complete follow-up data for 28-day and 90-day survival prediction. Six supervised machine learning classifiers, including linear discriminant analysis (LDA), support vector machine (SVM), random forest (RDF), decision tree (DST), adaptive boosting (ADA), and extremely randomized trees (EXT), were developed. Hyperparameters were optimized using grid search with five-fold stratified cross-validation. Performance was assessed using testing sets by evaluating the Brier score, precision, recall, F1-score, and AUC. SHapley Additive exPlanations (SHAP) were used for model interpretability, and the finalized models were deployed as web-based applications. Results: For SPC occurrence prediction, the EXT model demonstrated the best performance (AUC = 0.813). For 28-day mortality prediction, EXT achieved the highest discrimination (AUC = 0.921), whereas RDF performed best for 90-day mortality (AUC = 0.899). SHAP analysis identified preoperative hypertension, ECOG score, and intraoperative blood loss as the most influential predictors of SPC occurrence. Postoperative SOFA scores, APACHE II scores, and blood urea nitrogen (BUN) were key predictors of 28-day and 90-day mortality. PRESCO (https://presco.streamlit.app/), an online tool, provides real-time prediction of SPC and survival outcomes. Conclusions: We developed and validated machine learning models that accurately predict the occurrence and survival of SPCs in cancer patients after surgery. By deploying the online tool, clinicians can easily access it and utilize its functions to perform personalized risk stratification and guide perioperative decisions in oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.